Highlights to include antigenic and immunological characteristics of company’s unique stable prefusion F RSV subunit Groningen, the Netherlands, November 19, 2015 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, today presents key characteristics of its unique prefusion F antigen, the core… Continue reading Mucosis Presents Insights on Development of a Novel Needle-Free Vaccine for RSV Prevention at RSV Vaccines for World
Author: Willem van Lawick
Data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2015 Annual Meeting
Amsterdam, The Netherlands, November 3, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product… Continue reading Data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2015 Annual Meeting
Kiadis Pharma announces enrolment of first patient in its repeat-dosing Phase II clinical trial with ATIR101™
Amsterdam, The Netherlands, October 20, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the first patient has been enrolled into its repeat-dosing Phase II clinical trial, CR-AIR-008, with its… Continue reading Kiadis Pharma announces enrolment of first patient in its repeat-dosing Phase II clinical trial with ATIR101™
BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Advisory Committee Meeting Scheduled for November 24, 2015 SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (BMRN) today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the New Drug Application (NDA) for drisapersen. The FDA is currently reviewing… Continue reading BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Kiadis Pharma announces initiation of a repeat-dosing Phase II clinical trial with ATIR101™
Amsterdam, The Netherlands, September 30, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to… Continue reading Kiadis Pharma announces initiation of a repeat-dosing Phase II clinical trial with ATIR101™
